{"id":"aoc-1044","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reaction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AOC 1044 targets and modulates the expression of a specific gene, leading to its therapeutic effects.","oneSentence":"AOC 1044 is an investigational antisense oligonucleotide.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:28:39.387Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of myasthenia gravis"}]},"trialDetails":[{"nctId":"NCT07250737","phase":"","title":"Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping","status":"AVAILABLE","sponsor":"Avidity Biosciences, Inc.","startDate":"","conditions":"Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases","enrollment":""},{"nctId":"NCT05670730","phase":"PHASE1, PHASE2","title":"Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping","status":"COMPLETED","sponsor":"Avidity Biosciences, Inc.","startDate":"2022-11-09","conditions":"Duchenne Muscular Dystrophy, Exon 44","enrollment":70},{"nctId":"NCT06244082","phase":"PHASE2","title":"Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping","status":"ACTIVE_NOT_RECRUITING","sponsor":"Avidity Biosciences, Inc.","startDate":"2024-01-22","conditions":"DMD, Duchenne Muscular Dystrophy, Duchenne","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AOC 1044","genericName":"AOC 1044","companyName":"Avidity Biosciences, Inc.","companyId":"avidity-biosciences-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AOC 1044 is an investigational antisense oligonucleotide. Used for Treatment of myasthenia gravis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}